Samlyn Capital LLC bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 9,457,887 shares of the biopharmaceutical company’s stock, valued at approximately $11,728,000. Samlyn Capital LLC owned approximately 5.14% of Nektar Therapeutics at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the company. Candriam S.C.A. bought a new position in Nektar Therapeutics during the 2nd quarter worth about $99,000. Victory Capital Management Inc. bought a new position in Nektar Therapeutics during the 2nd quarter worth about $29,000. Rhumbline Advisers increased its holdings in Nektar Therapeutics by 3,377.0% during the 2nd quarter. Rhumbline Advisers now owns 185,116 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 179,792 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Nektar Therapeutics by 2,822.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock worth $684,000 after purchasing an additional 532,663 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in Nektar Therapeutics during the 2nd quarter worth about $56,000. Institutional investors own 75.88% of the company’s stock.
Nektar Therapeutics Price Performance
Shares of NASDAQ NKTR opened at $1.20 on Tuesday. The stock has a market capitalization of $220.82 million, a price-to-earnings ratio of -1.30 and a beta of 0.60. The business has a 50-day moving average of $1.27 and a 200-day moving average of $1.29. Nektar Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $1.93.
Analyst Ratings Changes
Separately, Rodman & Renshaw started coverage on Nektar Therapeutics in a report on Friday, June 28th. They issued a “buy” rating and a $2.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Nektar Therapeutics presently has an average rating of “Hold” and a consensus price target of $1.50.
Check Out Our Latest Stock Analysis on NKTR
Nektar Therapeutics Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Read More
- Five stocks we like better than Nektar Therapeutics
- The 3 Best Fintech Stocks to Buy Now
- 4 Reasons GlobalFoundries Could Be a Big Winner After Recent Lows
- Why Are These Companies Considered Blue Chips?
- The Average 401k Balance by Age Explained
- Trading Stocks: RSI and Why it’s Useful
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.